Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: Long-Term (4-Year) Data from a Phase 3 Study

Mcinnes IB, Kivitz AJ, Nash P, Rahman P, Rech J, Kirkham B, Navarra SV, Ding K, Ilsley E, Pricop L (2018)

Publication Type: Conference contribution

Publication year: 2018

Journal

Arthritis and Rheumatology Wiley

Book Volume: 70

Authors with CRIS profile

Hans Jürgen Rech Department of Medicine 3 – Rheumatology and Immunology

Involved external institutions

Memorial University of Newfoundland (MUN) CA Canada (CA) Guy's and St Thomas' (NHS Foundation Trust) GB United Kingdom (GB) University of Santo Tomas Hospital PH Philippines (PH) University of Queensland AU Australia (AU) University of Glasgow GB United Kingdom (GB) Altoona Center for Clinical Research US United States (USA) (US) Novartis AG CH Switzerland (CH)

How to cite

APA:

Mcinnes, I.B., Kivitz, A.J., Nash, P., Rahman, P., Rech, J., Kirkham, B.,... Pricop, L. (2018). Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: Long-Term (4-Year) Data from a Phase 3 Study.

MLA:

Mcinnes, Iain B., et al. "Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: Long-Term (4-Year) Data from a Phase 3 Study." 2018.

BibTeX: Download